Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients.

@article{Engelen2003FourCO,
  title={Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients.},
  author={Wendy Engelen and Gert A. Verpooten and Marc G Van der Planken and Mark F Helbert and Jean Louis Bosmans and Marc E. De Broe},
  journal={Clinical nephrology},
  year={2003},
  volume={60 2},
  pages={119-24}
}
Mycophenolate mofetil (MMF) is one of the new immunosuppressive drugs used in renal transplantation. MMF inhibits the de novo purine synthesis. Since this purine synthesis in lymphocytes entirely depends on the de novo pathway, MMF is considered to cause a selective inhibition of T- and B lymphocytes. Recently, 4 transplant patients out of 30 developed a severe anemia in the early post-transplantation period. Their immediate post-transplantation immunosuppression consisted of corticosteroids… CONTINUE READING